Startups

Character Biosciences logo

Character Biosciences

Character Biosciences develops precision medicines for progressive polygenic diseases, initially focusing on age-related macular degeneration and primary open-angle glaucoma. It combines human genetics, longitudinal clinical data, retinal imaging and AI-driven modeling to identify disease subtypes, discover therapeutic targets and select patients for clinical trials. Its pipeline includes CTX114, a complement inhibitor for geographic atrophy, and CTX203, a lipid modulator intended to prevent progression to advanced age-related macular degeneration.

Team

Aakriti SinghResearch Associate
Adria FrazierSenior Research Associate
Andrea NeeranjanAssociate Director, Clinical Research
Brendan CurranEngineering Lead
Cheng ZhangChief Executive Officer, Co-Founder and Board Member
Daniel ElgortChief Data and Analytics Officer
David BuchholzSenior Scientist
Dinah ChenMedical Director and Clinical Innovation Lead
Dylan HenryContracts Manager
Erik KarrerSVP, Drug Discovery
Geraldine TaverasSenior Clinical Research Coordinator
Isabel VarelaOperations Analyst
Jamie KasuboskiBoard Member
Jasmin BharadiyaSenior Data Engineer
Jason P. HaflerJason P. HaflerBoard Member
Jessamyn WeadHead of People
Josh BuddleHead of Clinical Network and Longitudinal Research
Julia MyersSenior Research Associate
Kaila SmilenVP, Corporate Development
Laura MacriAssociate Director, Study Operations
Marcel van der BrugScientific Advisor, Co-Founder
Maria AvrutskySenior Scientist
May ChenDirector, Drug Discovery
Mayssa AttarBoard Member
Nathaniel MooiSenior Research Associate
Nick JohnsonNick JohnsonTechnology Advisor, Co-Founder
Nick OlsenNick OlsenBoard Member
Peter DiLauraBoard Member
Reut ShemaBoard Member
Robert KimChief Medical Officer
Ryan CampbellSenior Research Associate
Sumra FarooqClinical Data Manager
Tejasveeta NadkarniAssociate Scientist
Vivek GaripalliBoard Member
Wendy LinAssociate Director, Clinical Operations and Clinical Science
Yunju YangHuman Genetics Lead
Zachary KatzDirector, Strategic Initiatives & Alliance Management

Investments